Antithrombin Therapy for Severe Preeclampsia
Authors:
- 1 January 2000
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 84 (10) , 583-590
Abstract
A double-blind, randomized, placebo-controlled trial was conducted to evaluate whether treatment with Antithrombin (AT) concentrates improved the clinical and perinatal outcome in patients with severe preeclampsia. Severe preeclamptic patients (24 to 35 weeks of gestation, Gestosis Index (GI) > 6 points) were randomized into two groups: 66 received AT and 67 received placebo. There were no statistical differences in the clinical profiles of the two groups. Study drugs were given intravenously once daily for 7 consecutive days. Maternal symptoms were evaluated from the difference of GI between before and after treatment, and fetal findings were evaluated from the changes of the biophysical profile score and the estimated fetal weight gain. Improvement was significantly greater in the AT group for both the GI (p = 0.020) and the estimated fetal weight gain (p = 0.029). The improvement of coagulation parameters was also evaluated. The D-dimer levels increased significantly in the placebo group (p = 0.026), but did not change in the AT group. Gestation was significantly prolonged (p = 0.007), and the number of low-birth weight infants was significantly smaller (p = 0.011) in the AT group. No adverse events related to AT were observed. It is revealed that AT concentrate therapy for preeclampsia is effective and safe, leading to an improved perinatal outcome. * The members of BI51.017 study group are listed in the Appendix, on pp. 588–9.Keywords
This publication has 25 references indexed in Scilit:
- Coagulation/Fibrinolysis Disorder in Patients with Severe PreeclampsiaSeminars in Thrombosis and Hemostasis, 1999
- Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsiaBlood Coagulation & Fibrinolysis, 1997
- Antithrombin III Prevents Renal Dysfunction and Hypertension Induced by Enhanced Intravascular Coagulation in Pregnant Rats: Pharmacological Confirmation of the Benefits of Treatment with Antithrombin III in PreeclampsiaJournal of Cardiovascular Pharmacology, 1996
- Recent developments in the pathophysiology and management of pre-eclampsiaBritish Journal of Anaesthesia, 1996
- Platelet activation and vascular damage in gestational hypertensionAmerican Journal of Obstetrics and Gynecology, 1992
- Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy- induced hypertensionAmerican Journal of Obstetrics and Gynecology, 1991
- Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activationCell, 1991
- The Relationship between Clinical Signs and Hypercoagulable State in Toxemia of PregnancyGynecologic and Obstetric Investigation, 1991
- Formulas for fetal weight estimation by ultrasound measurements based on neonatal specific gravities and volumesAmerican Journal of Obstetrics and Gynecology, 1987
- Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidityAmerican Journal of Obstetrics and Gynecology, 1984